AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15788681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 12004808 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of morphine (1 mg x m(‐1)) and ketamine (0.75 mg x m(‐1)) via PCAS
Number of subjects: 42
Study 12004808 — intervention group
Group type: COMPARATOR
Intervention: Morphine (1 mg x m(‐1)) via PCAS
Number of subjects: 42
Study 12004808 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of morphine and ketamine
Number of subjects: 42
Study 12004808 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 42
Study 10465376 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 140
Study 10465376 — intervention group
Group type: COMPARATOR
Intervention: Control (non-recipient volunteers)
Number of subjects: 140
Study 7789048 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary control of breathing task using a spirometer
Number of subjects: 8
Study 7789048 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual tracking task using a joystick (control task)
Number of subjects: 8
Study 7789048 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy subjects
Number of subjects: 8
Study 2189149 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose alternate-day prednisolone
Number of subjects: 107
Study 2189149 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 107
Study 7322959 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide, 2.5 mg daily
Number of subjects: 0
Study 7322959 — intervention group
Group type: COMPARATOR
Intervention: Cyclopenthiazide, 0.5 mg daily
Number of subjects: 0
Study 31694568 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM®-guided blood-component transfusion protocol
Number of subjects: 104
Study 31694568 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM®-guided treatment in patients with long CPB-times (> 115 min.; n = 55)
Number of subjects: 104
Study 31694568 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard coagulation testing algorithm)
Number of subjects: 104
Study 27428710 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) treatment
Number of subjects: 144
Study 26037941 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib and trametinib
Number of subjects: 423
Study 26037941 — intervention group
Group type: COMPARATOR
Intervention: Dabrafenib only
Number of subjects: 423
Study 24048773 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg orally twice daily for 3 days
Number of subjects: 88
Study 24048773 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally twice daily for 3 days
Number of subjects: 88
Study 21861920 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and in-home/telephone follow-up intervention group
Number of subjects: 0
Study 21861920 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only intervention group
Number of subjects: 0
Study 21861920 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home/telephone follow-up only intervention group
Number of subjects: 0
Study 21861920 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study 19533304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous moderate doses of human recombinant Epo (epoietin-alpha, 100 or 200 IU/kg/die)
Number of subjects: 102
Study 19533304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 16337715 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IGF-I levels (measured by molar ratio of IGF-I to IGFBP-3)
Number of subjects: 590
Study 16506463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan Cervical Disc System
Number of subjects: 33
Study 16506463 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 33
Study 12677302 — intervention group
Group type: EXPERIMENTAL
Intervention: [(18)F]FDG PET
Number of subjects: 15
Study 12677302 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 15
Study 10793596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 0
Study 10793596 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 0
Study 9012323 — intervention group
Group type: EXPERIMENTAL
Intervention: Mancozeb exposure
Number of subjects: 0
Study 9012323 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1334283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 828
Study 1334283 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 828
Study 6696610 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic conditioning method using bell and pad
Number of subjects: 60
Study 6696610 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant conditioning method with unconditioned stimulus delay of 3 minutes
Number of subjects: 60
Study 6696610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 31580316 — intervention group
Group type: EXPERIMENTAL
Intervention: FITÂ® Lady patch (active patch)
Number of subjects: 40
Study 31580316 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (control)
Number of subjects: 40
Study 28987358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented plant extract (FPE) 60 mL
Number of subjects: 44
Study 24443392 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI diet
Number of subjects: 265
Study 24443392 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 265
Study 23445275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk protein (CMP) elimination diet (n=14)
Number of subjects: 29
Study 23445275 — intervention group
Group type: COMPARATOR
Intervention: Free diet (n=15)
Number of subjects: 29
Study 23445275 — intervention group
Group type: EXPERIMENTAL
Intervention: CMP elimination diet
Number of subjects: 29
Study 23445275 — intervention group
Group type: COMPARATOR
Intervention: Free diet
Number of subjects: 29
Study 21871686 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5mg daily plus metformin
Number of subjects: 570
Study 21871686 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus metformin
Number of subjects: 570
Study 18974285 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/day and Olmesartan 40 mg/day administered separately for 10 days
Number of subjects: 5
Study 18974285 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose combination of Amlodipine/Olmesartan 10 mg/40 mg
Number of subjects: 5
Study 18974285 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose combination tablet taken 30 minutes after a high-fat breakfast
Number of subjects: 5
Study 18974285 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 10 mg to 40 mg with Amlodipine 5 mg to 10 mg
Number of subjects: 5
Study 17102570 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestimide (3 g/day)
Number of subjects: 0
Study 17102570 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (10 mg)
Number of subjects: 0
Study 14767300 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg controlled release melatonin at night
Number of subjects: 20
Study 14767300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11567544 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures (including osteotomies, debridement by arthroscopy and arthotomy, joint replacement)
Number of subjects: 0
Study 11567544 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement by arthroscopy and arthotomy
Number of subjects: 0
Study 11567544 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint replacement
Number of subjects: 0
Study 11567544 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (control group)
Number of subjects: 0
Study 9438709 — intervention group
Group type: EXPERIMENTAL
Intervention: REPRODUCTION
Number of subjects: 8
Study 9438709 — intervention group
Group type: EXPERIMENTAL
Intervention: TRACKING
Number of subjects: 8
Study 8123393 — intervention group
Group type: EXPERIMENTAL
Intervention: Video training with closed circuit television (CCTV)
Number of subjects: 20
Study 8123393 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 20
Study 2824710 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/etoposide (PE)
Number of subjects: 144
Study 2824710 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide/etoposide (IE)
Number of subjects: 144
Study 31923074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (5%) applied at least 10 minutes before biopsy
Number of subjects: 106
Study 31923074 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine injection (1%) administered at least 1 minute prior to biopsy
Number of subjects: 106
Study 31923074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (5%)
Number of subjects: 106
Study 31923074 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine injection (1%)
Number of subjects: 106
Study 29299888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block (PDB-Group) with 0.3 ml/kg 0.25% bupivacaine
Number of subjects: 78
Study 29299888 — intervention group
Group type: COMPARATOR
Intervention: Penile nerve block (PNB-Group) with 0.3 ml/kg 0.25% bupivacaine
Number of subjects: 78
Study 26701344 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care (PCC) intervention
Number of subjects: 177
Study 26701344 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 177
Study 25908323 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfotiamine (BF) 600mg
Number of subjects: 85
Study 25908323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 85
Study 25908323 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfotiamine (BF)
Number of subjects: 85
Study 24074927 — intervention group
Group type: EXPERIMENTAL
Intervention: WP‐CRT
Number of subjects: 44
Study 24074927 — intervention group
Group type: EXPERIMENTAL
Intervention: WP‐IMRT
Number of subjects: 44
Study 21917759 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAG (prednisone, vinblastine, doxorubicin, gemcitabine)
Number of subjects: 59
Study 18162657 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive stereotypical beliefs toward Asian Americans in a realistic threat context
Number of subjects: 0
Study 18162657 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement of both positive and negative stereotypes of Asian Americans
Number of subjects: 0
Study 18162657 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental situations involving interactions with Asian Americans in realistic threat contexts
Number of subjects: 0
Study 17018669 — intervention group
Group type: EXPERIMENTAL
Intervention: Home safety program (n = 100 participants)
Number of subjects: 391
Study 17018669 — intervention group
Group type: COMPARATOR
Intervention: Social visits (n = 96)
Number of subjects: 391
Study 14679105 — intervention group
Group type: EXPERIMENTAL
Intervention: Q fever complement-fixing antigen (QFA)
Number of subjects: 0
Study 14679105 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunostimulants (general category including QFA)
Number of subjects: 0
Study 11094866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotrol NS (3 mg nicotine)
Number of subjects: 20
Study 11094866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8818489 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline hydrochloride 0.1%
Number of subjects: 9
Study 8818489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 0.075%
Number of subjects: 9
Study 8818489 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study 1317765 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (2 g)
Number of subjects: 15
Study 1317765 — intervention group
Group type: COMPARATOR
Intervention: Control (normotensive group)
Number of subjects: 15
Study 3830478 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory attention
Number of subjects: 22
Study 3830478 — intervention group
Group type: COMPARATOR
Intervention: Visual distraction
Number of subjects: 22
Study 30509375 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency physician ultrasound for the identification of gastric contents
Number of subjects: 45
Study 30509375 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert review of ultrasound images
Number of subjects: 45
Study 30566730 — intervention group
Group type: EXPERIMENTAL
Intervention: PSE (900mg/day for 17 days)
Number of subjects: 10
Study 30566730 — intervention group
Group type: EXPERIMENTAL
Intervention: PSE
Number of subjects: 10
Study 30566730 — intervention group
Group type: COMPARATOR
Intervention: PL (placebo, equivalent amount for 17 days)
Number of subjects: 10
Study 30566730 — intervention group
Group type: COMPARATOR
Intervention: PL
Number of subjects: 10
Study 27417562 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction diet (goal: 10% weight loss), N = 118
Number of subjects: 439
Study 27417562 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (225 minutes/week of moderate-to-vigorous activity), N = 117
Number of subjects: 439
Study 27417562 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diet + exercise, N = 117
Number of subjects: 439
Study 27417562 — intervention group
Group type: COMPARATOR
Intervention: Control, N = 87
Number of subjects: 439
Study 24925079 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber Hand Illusion (RHI) in BDD group
Number of subjects: 17
Study 24925079 — intervention group
Group type: COMPARATOR
Intervention: Rubber Hand Illusion (RHI) in healthy control group
Number of subjects: 17
Study 24925079 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber Hand Illusion (RHI)
Number of subjects: 17
Study 21954995 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with body weight support (TTBWS) plus traditional training
Number of subjects: 60
Study 21954995 — intervention group
Group type: COMPARATOR
Intervention: Traditional training alone
Number of subjects: 60
Study 20099987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg/day
Number of subjects: 59
Study 20099987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/day
Number of subjects: 59
Study 20099987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 320 mg/day
Number of subjects: 59
Study 20099987 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2.5 mg/day
Number of subjects: 59
Study 20099987 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 15 mg/day
Number of subjects: 59
Study 20099987 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 30 mg/day
Number of subjects: 59
Study 19026036 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin 25 mg twice daily
Number of subjects: 37
Study 19026036 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin 50 mg twice daily
Number of subjects: 37
Study 19026036 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin 75 mg twice daily
Number of subjects: 37
Study 16189072 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) 800 mg/day
Number of subjects: 56
Study 16189072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 12925463 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh; an endothelium‐dependent vasodilator) administered via transdermal iontophoresis in infants born at term (n=19)
Number of subjects: 54
Study 12925463 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh; an endothelium‐dependent vasodilator) administered via transdermal iontophoresis in infants born preterm (n=35)
Number of subjects: 54
Study 11716647 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) and waist-hip ratio (WHR) as predictors of serum triglycerides
Number of subjects: 831
Study 11716647 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance run test (physical fitness) as a predictor of serum HDL-C
Number of subjects: 831
Study 11716647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of adipose polyunsaturated fatty acids as a measure of long-term dietary fat intake
Number of subjects: 831
Study 11716647 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity and fat centrality
Number of subjects: 831
Study 9189190 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary case management with individualized care plans
Number of subjects: 70
Study 9189190 — intervention group
Group type: COMPARATOR
Intervention: Standard emergency care (control)
Number of subjects: 70
Study 8263271 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal vitamins (TRN, Natalins Rx, Filibon Forte, Prenatal Formula, Materna, Stuartnatal)
Number of subjects: 9
Study 8263271 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 g table salt)
Number of subjects: 9
Study 8263271 — intervention group
Group type: COMPARATOR
Intervention: Sucrose capsule (1 g sucrose)
Number of subjects: 9
Study 8263271 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2000 mg)
Number of subjects: 9
Study 3577722 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weight bearing
Number of subjects: 46
Study 3577722 — intervention group
Group type: COMPARATOR
Intervention: Late weight bearing
Number of subjects: 46
Study 28466569 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylase added to SC+ porridges
Number of subjects: 120
Study 28466569 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylase added to SC porridges
Number of subjects: 120
Study 28466569 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylase added to porridges
Number of subjects: 120
Study 28466569 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylase-added porridges
Number of subjects: 120
Study 28466569 — intervention group
Group type: COMPARATOR
Intervention: Control SC+ porridges
Number of subjects: 120
Study 28466569 — intervention group
Group type: COMPARATOR
Intervention: Control SC porridges
Number of subjects: 120
Study 27237345 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrating evidence‐based practice into research
Number of subjects: 120
Study 27237345 — intervention group
Group type: COMPARATOR
Intervention: Traditional research (Control)
Number of subjects: 120
Study 24731521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (2 g over 20 minutes)
Number of subjects: 1109
Study 24731521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised magnesium sulphate (3 × 500 mg over 1 hour)
Number of subjects: 1109
Study 24731521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (standard therapy alone)
Number of subjects: 1109
Study 24731521 — intervention group
Group type: COMPARATOR
Intervention: Intravenous magnesium sulphate vs Placebo
Number of subjects: 1109
Study 24731521 — intervention group
Group type: COMPARATOR
Intervention: Nebulised magnesium sulphate vs Placebo
Number of subjects: 1109
Study 23111204 — intervention group
Group type: EXPERIMENTAL
Intervention: Rességuier Method (RM) followed by Qi Gong (QG)
Number of subjects: 30
Study 23111204 — intervention group
Group type: EXPERIMENTAL
Intervention: Qi Gong (QG) followed by Rességuier Method (RM)
Number of subjects: 30
Study 21152828 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Trifolium pratense, 1 capsule/day
Number of subjects: 120
Study 21152828 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules containing lactose, 1 capsule/day
Number of subjects: 120
Study 18257183 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal cluster‐needling
Number of subjects: 87
Study 18257183 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Prostat Tablets)
Number of subjects: 87
Study 15927388 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention (15 weeks)
Number of subjects: 53
Study 15927388 — intervention group
Group type: COMPARATOR
Intervention: No intervention (15 weeks)
Number of subjects: 53
Study 12637480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous irinotecan (40 to 125 mg/m2 every 2 weeks) plus oral ciclosporin (5 mg/kg bid for 3 days)
Number of subjects: 37
Study 12637480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous irinotecan plus oral ciclosporin
Number of subjects: 37
Study 12637480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous irinotecan
Number of subjects: 37
Study 12237188 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 247
Study 12237188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 247
Study 12237188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 10533946 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention on antibiotic use
Number of subjects: 157
Study 10533946 — intervention group
Group type: COMPARATOR
Intervention: Unrelated topic intervention (Control)
Number of subjects: 157
Study 8636523 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens Servo 900 C (SC)
Number of subjects: 9
Study 8636523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ohmeda CPU 1 (CPU)
Number of subjects: 9
Study 8636523 — intervention group
Group type: EXPERIMENTAL
Intervention: Engström Erica (EE)
Number of subjects: 9
Study 2258877 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling
Number of subjects: 28
Study 7368972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioselective beta-blockade
Number of subjects: 87
Study 7368972 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 87
Study 7368972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 7368972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioselective beta-blockade, Diazepam, Placebo
Number of subjects: 87
Study 7368972 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment after onset of symptoms
Number of subjects: 87
Study 6098034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g im) plus daily placebo injections with probenicid (1 g orally)
Number of subjects: 20
Study 6098034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g im on each of three days) plus probenicid (1 g orally)
Number of subjects: 20